Evidence map›Paper›PMID 35928285›Full record

ArticleContemporary clinical trials communications2022

A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology.

Rahma Warsame, Joselle Cook, Briant Fruth, Joleen Hubbard, Katrina Croghan, Katharine A R Price, Aminah Jatoi, Shaji Kumar, Carrie Thompson, Jan Buckner and 3 more

Open access · goldAbstract read
In one paragraph

Article in Contemporary clinical trials communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Electronic patient-reported outcome platforms used in hematological cancers: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Joselle CookDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Briant FruthDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Joleen HubbardDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Katrina CroghanDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Katharine A R PriceDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Aminah JatoiDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Carrie ThompsonDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Jan BucknerDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Jeff SloanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Amylou C DueckDepartment of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA.
Mayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Background: Clinicians have limited time during patient encounters which can result in patients' concerns not being addressed. This study's objective was to test whether an electronic patient-reported outcome quality of life tool (PROQOL) in which patients identify their primary concern during clinic visits improves cancer patient quality of life (QOL). Patients and methods: This single center non-blinded prospective clinical trial randomized patients (2:1) to PROQOL versus usual care (UC). Two patient cohorts were enrolled: those with hematologic malignancies (multiple myeloma [MM] or light chain amyloidosis [AL]) and solid tumors (head and neck [H/N] or gynecologic [GYN] malignancies). Primary endpoint was patient-reported QOL at 12 months measured by a single-item Linear Analog Self-Assessment. Value to patients and impact on clinician workflow was measured using a "was it worth it" survey. The study was powered to detect a 0.5 standard deviation difference between groups. Results: Overall 383 patients were enrolled, 171 with MM, 62 AL, 113 GYN, and 37 H/N between July 2016 and April 2018, with 12-month follow-up. There were 171 (44.6%) male patients and median age was 62 years (range 31-87). The most often selected concern was physical health (30.9%), and second was cancer diagnosis and treatment (29.1%). Mean QOL was 7.12 for PROQOL and 6.98 for UC (0-10 scale) at 12 months, with no between-group difference overall (p = 0.56) or within hematologic or solid tumor cohorts, respectively. Among patients, 74% thought the PROQOL tool was worthwhile, 86% would choose PROQOL again, and 81% would recommend it to others. Among clinicians, 95% responded that PROQOL was worthwhile and did not think that PROQOL negatively impacted their workflow. Conclusions: Although we did not demonstrate a QOL difference between PROQOL and UC groups; the PROQOL tool held considerable value in identifying patients' main concerns over time and was worthwhile for patients and clinicians.

Indexed as

AL, Light chain amyloidosisGYN, Gynecologic malignanciesHealth care deliveryH/N, Head and Neck malignancyMM, Multiple myelomaPatient-reported outcomesQuality of life

Identifiers

PMID35928285
PMCPMC9344350
OpenAlexW4285403989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.